Related Experiment Video
Updated: Jul 3, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Immune response to lytic peptides conjugated to a betaCG fragment in treated BALB/C mice
Marek Bogacki1, Frederic M Enright, William J Todd
1Institute of Animal Reproduction and Food Research, PAS, Tuwima St. 10, Olsztyn 10-747, Poland. marbo@pan.olsztyn.pl
Abstract:
Hecate-betaCG and Phor14-betaCG(ala) are relatively short, amphipathic alpha-helical cationic peptides with the ability to destroy selectively breast, prostate and ovarian cancer cells. Treatment with proteins and peptides frequently initiated antibody formation. Short peptides may minimize the risk of the immune system mobilization after treatment but it is necessary to investigate whether Hecate-betaCG and Phor14-betaCG(ala) induce the immune system to produce antibody and whether they affect the reproductive organs in normal wild-type mice. The results of our experiments showed that specific antibodies, tested by the enzyme-immunoassay, were not detected in the group treated with Hecate-betaCG and Phor14-betaCG(ala). The blood concentrations of both peptides begun to decrease from 60 minutes after injection and after 240 minutes its levels were undetectable. Histopatho-logical examination exhibited degenerative changes in the prostate glands and testes in males and in the ovaries and uteri of females treated with both peptides. In conclusion, our results indicate that both relatively small and rapidly metabolized peptides are not immunogenic and can be used for further investigation as a potential cancer treatment.
Insights
Hecate-betaCG and Phor14-betaCG(ala) peptides show potential for cancer treatment by selectively destroying cancer cells. These peptides were found to be non-immunogenic and rapidly metabolized, with no antibody formation observed in mice.
Area of Science:
- Biochemistry
- Oncology
- Immunology
Background:
- Hecate-betaCG and Phor14-betaCG(ala) are short, amphipathic alpha-helical cationic peptides.
- These peptides demonstrate selective cytotoxicity against breast, prostate, and ovarian cancer cells.
Purpose of the Study:
- To investigate the immunogenicity of Hecate-betaCG and Phor14-betaCG(ala).
- To assess the effects of these peptides on reproductive organs in normal wild-type mice.
Main Methods:
- Enzyme-immunoassay was used to detect specific antibodies.
- Blood concentrations of the peptides were monitored over time.
- Histopathological examinations were performed on reproductive organs.
Main Results:
- No specific antibodies were detected in mice treated with Hecate-betaCG and Phor14-betaCG(ala).
- Peptide blood concentrations decreased significantly, becoming undetectable within 240 minutes.
- Degenerative changes were observed in the prostate glands, testes, ovaries, and uteri of treated mice.
Conclusions:
- Hecate-betaCG and Phor14-betaCG(ala) are non-immunogenic and rapidly metabolized.
- Despite observed reproductive organ changes, their non-immunogenic nature supports further investigation as potential cancer therapeutics.

